| Sulfinpyrazone in the prevention of sudden death after myocardial infarction. The Anturane Reinfarction Trial Research Group. | |
| | |
MedLine Citation:
|
PMID: 6985706 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We report the results of a randomized double-blind, multicenter trial comparing sulfinpyrazone (200 mg four times a day) and a placebo in the prevention of cardiac mortality among 1558 patients followed for an average of 16 months, beginning 25 to 35 days after a documented myocardial infarction. All but one of the 106 deaths in the group were cardiac; 59 were sudden. The reduction in cardiac mortality at 24 months in the sulfinpyrazone group was 32 per cent (P = 0.058), and the reduction in sudden death was 43 per cent (P = 0.041). The benefit of sulfinpyrazone was attributable entirely to a reduction in sudden death during the second through seventh months after infarction, when there were 35 cardiac deaths in the placebo group and 17 in the sulfinpyrazone group (P = 0.021); of these deaths, 24 in the placebo group and six in the sulfinpyrazone group were sudden cardiac deaths -- a sulfinpyrazone-induced 74 per cent reduction in the calculated mortality rate (P = 0.003). We conclude that sulfinpyrazone prevents sudden cardiac death during the high-risk period shortly after an acute myocardial infarction, but that there is no further apparent effect beyond the seventh month after infarction. |
| | |
Authors:
|
- |
Related Documents
:
|
1711966 - Mechanisms of sudden cardiac death. 17868806 - Limitations of ejection fraction for prediction of sudden death risk in patients with c... 7595296 - Coronary artery thromboembolism and unexpected death in childhood and adolescence. 8020766 - Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia-revis... 10600866 - S-t segment voltage during sequential coronary occlusions is an unreliable marker of pr... 9104896 - Use of evidence-based medical therapy in patients undergoing percutaneous coronary reva... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: The New England journal of medicine Volume: 302 ISSN: 0028-4793 ISO Abbreviation: N. Engl. J. Med. Publication Date: 1980 Jan |
Date Detail:
|
Created Date: 1980-02-28 Completed Date: 1980-02-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 250-6 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Clinical Trials as Topic Death, Sudden* Double-Blind Method Female Follow-Up Studies Humans Male Middle Aged Myocardial Infarction / drug therapy, mortality* Patient Compliance Patient Readmission Placebos Random Allocation Sulfinpyrazone / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Placebos; 57-96-5/Sulfinpyrazone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrah...
Next Document: Translational control of proinsulin synthesis by glucose.